Ocular Inflammation and Pain - Pipeline Insight, 2024

This “Ocular Inflammation and Pain - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Ocular Inflammation and Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Ocular Inflammation and Pain Understanding

Ocular Inflammation and Pain: Overview

Inflammation is body’s response to injury, infection or irritation. In some cases, inflammation can occur in response to normally harmless substances, such as dust, grass or pollen. This is an allergic reaction. The immune system may also trigger inflammation in response to the body’s own tissues. This is called an autoimmune reaction. Eye inflammation occurs in response to infection, allergies, autoimmune disorders, irritation, or injury or trauma to the eye or eyelid. Symptoms of eye inflammation can affect the eyes, eyelids, or surrounding tissues and include: Blurry vision, Pain, Redness, Swelling, Tearing, Unusual warmth or heat. Ocular inflammation is also often present in patients with systemic inflammatory diseases, such as rheumatoid arthritis, systemic lupus erythematosus, sarcoidosis, Wegener’s granulomatosis, Sjögren’s syndrome, polyarteritis nodosa, primary antiphospholipid syndrome, Behçet’s syndrome, Kawasaki disease, Cogan’s syndrome, and relapsing polychondritis.

Ocular Inflammation and Pain - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ocular Inflammation and Pain pipeline landscape is provided which includes the disease overview and Ocular Inflammation and Pain treatment guidelines. The assessment part of the report embraces, in depth Ocular Inflammation and Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ocular Inflammation and Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Ocular Inflammation and Pain R&D. The therapies under development are focused on novel approaches to treat/improve Ocular Inflammation and Pain.

Ocular Inflammation and Pain Emerging Drugs Chapters

This segment of the Ocular Inflammation and Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ocular Inflammation and Pain Emerging Drugs

APP13007: Formosa pharmaceuticalsAPP13007, derived from our proprietary APNT formulation platform, is an aqueous-based ophthalmic nanosuspension positioned for the treatment of post-operative pain and inflammatory eye conditions. The active ingredient in APP13007 is a potent corticosteroid agent whose efficacy and safety for dermatological use has been well established for more than 30 years in the US, Europe, and Japan. APP13007 will represent the first ophthalmic application of the known API. APP13007 completed Phase II studies in 2020 and has just started Phase III studies in the United States in March, 2021.

Ocular Inflammation and Pain: Therapeutic Assessment

This segment of the report provides insights about the different Ocular Inflammation and Pain drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Ocular Inflammation and Pain

There are approx. 5+ key companies which are developing the therapies for Ocular Inflammation and Pain. The companies which have their Ocular Inflammation and Pain drug candidates in the most advanced stage, i.e. Phase III include, Formosa pharmaceuticals.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Ocular Inflammation and Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ocular Inflammation and Pain: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ocular Inflammation and Pain therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ocular Inflammation and Pain drugs.

Ocular Inflammation and Pain Report Insights

• Ocular Inflammation and Pain Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Ocular Inflammation and Pain Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Ocular Inflammation and Pain drugs?
• How many Ocular Inflammation and Pain drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ocular Inflammation and Pain?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ocular Inflammation and Pain therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Ocular Inflammation and Pain and their status?
• What are the key designations that have been granted to the emerging drugs?